| 07/01/2025 11:30 |
New Launch of TAVALISSE for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea |
| 06/24/2025 15:30 |
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers |
| 06/02/2025 08:00 |
Notice of Convocation Annual General Meeting 2025 |
| 05/08/2025 16:00 |
Financial Briefing for the Fiscal Year Ended March 31, 2025 (Fiscal 2024) |
| 05/08/2025 10:00 |
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System |
| 05/07/2025 16:30 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [Japanese GAAP] |
| 05/07/2025 16:30 |
Supplementary Explanatory Materials on Financial Results for the Fiscal Year Ended March 31, 2025 |
| 05/07/2025 16:30 |
Notice Concerning Dividends of Surplus (Increase in Dividend) |
| 05/07/2025 16:30 |
Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading |
| 05/07/2025 16:30 |
Notice Concerning Revision of the Executive Compensation System |
| 02/26/2025 15:30 |
Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan |
| 02/03/2025 15:30 |
Supplementary Explanatory Materials on Financial Results for the Nine Months Ended December 31, 2024 |
| 02/03/2025 15:30 |
Consolidated Financial Results for the Nine Months Ended December 31, 2024 [Japanese GAAP] |
| 01/21/2025 11:30 |
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea |
| 01/14/2025 11:30 |
Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations |
| 01/07/2025 15:30 |
Sub-licensing Agreement for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE with Tai Tien Pharmaceuticals in Taiwan |
| 12/23/2024 08:45 |
Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist YSELTY (generic name linzagolix). |
| 11/06/2024 16:00 |
Financial Briefing for the Second Quarter(Interim) of the Fiscal Year Ended March 31, 2025 (Fiscal 2024) |
| 11/06/2024 10:00 |
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System(ToSTNeT-3) |
| 11/05/2024 16:30 |
Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) |
| 11/05/2024 16:30 |
Supplementary Explanatory Materials on Financial Results for the Six Months Ended September 30, 2024 |
| 11/05/2024 16:30 |
Consolidated Financial Results for the Six Months Ended September 30, 2024 [Japanese GAAP] |
| 09/17/2024 08:45 |
Launch of YSELTY (generic name linzagolix) for uterine fibroid treatment in Europe |
| 09/09/2024 14:00 |
Drug discovery research collaboration agreement with Reborna Biosciences, Inc. |
| 09/04/2024 08:45 |
Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug |
| 07/30/2024 15:00 |
Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2024 |
| 07/30/2024 15:00 |
Consolidated Financial Results for the Three Months Ended June 30, 2024 [Japanese GAAP] |
